Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 5/20 | 0.31 |
| ▸ | CA2 | P00918 | 5/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15514032 | 0.97 | MVD (0.40) | MVDNOS3NOS1NOS2CA1 | |
| SCHEMBL28000874 | 0.97 | MVD (0.40) | MVDNOS3NOS1NOS2CA1 | |
| Water SCHEMBL28582154 | 0.97 | MVD (0.40) | MVDNOS3NOS1NOS2CA1 | |
| SCHEMBL1065720 | 0.95 | MVD (0.39) | MVDNOS3NOS1NOS2CA1 | |
| SCHEMBL29050786 | 0.95 | MVD (0.39) | MVDNOS3NOS1NOS2CA1 | |
| SCHEMBL4110528 | 0.90 | NOS3 (0.38) | MVDNOS3NOS1NOS2CA1 | |
| Water SCHEMBL28318017 | 0.88 | NOS3 (0.37) | MVDNOS3NOS1NOS2CA1 | |
| SCHEMBL29007316 | 0.88 | NOS3 (0.37) | MVDNOS3NOS1NOS2CA1 | |
| SCHEMBL4966699 | 0.87 | MVD (0.36) | MVDNOS3NOS1NOS2CA1 | |
| SCHEMBL27190 | 0.86 | CA4 (0.40) | MVDNOS3NOS1NOS2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114150040-A | Crystallization-resistant creatine kinase detection kit and preparation method thereof | 中生北控生物科技股份有限公司 | 2022-03-08 | — | — | CN | disclosed |
| US-9476870-B2 | Methods and agents for screening for compounds capable of modulating gene expression | PTC THERAPEUTICS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| EP-2351859-B1 | Methods and agents for screening for compounds capable of modulating gene expression | PTC THERAPEUTICS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20150253304-A1 | Methods And Agents For Screening For Compounds Capable Of Modulating Gene Expression | PTC THERAPEUTICS, INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-9068234-B2 | Methods and agents for screening for compounds capable of modulating gene expression | PTC THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2806036-A1 | Methods and agents for screening for compounds capable of modulating VEGF expression | PTC Therapeutics, Inc. (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2400038-B1 | Methods and nucleic acid constructs for screening for compounds capable of modulating VEGF expression | PTC THERAPEUTICS INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8426194-B2 | Expression vector coding a negative regulator and/or postranslational regulatory elements for use in identifying modulators of endothelial growth factors | PTC THERAPEUTICS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2400038-A1 | Methods and nucleic acid constructs for screening for compounds capable of modulating VEGF expression | PTC Therapeutics, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2351859-A1 | Methods and agents for screening for compounds capable of modulating gene expression | PTC Therapeutics, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-1786933-A4 | METHODS AND AGENTS FOR SCREENING FOR COMPOUNDS CAPABLE OF MODULATING GENE EXPRESSION | PTC THERAPEUTICS INC (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1786933-A1 | METHODS AND AGENTS FOR SCREENING FOR COMPOUNDS CAPABLE OF MODULATING GENE EXPRESSION | PTC Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070072186-A1 | Methods and agents for screening for compounds capable of modulating her2 expression | PTC THERAPEUTICS, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1761638-A2 | METHODS AND AGENTS FOR SCREENING FOR COMPOUNDS CAPABLE OF MODULATING VEGF EXPRESSION | PTC Therapeutics, Inc. (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006022712-A1 | METHODS AND AGENTS FOR SCREENING FOR COMPOUNDS CAPABLE OF MODULATING GENE EXPRESSION | PTC THERAPEUTICS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005118857-A2 | METHODS AND AGENTS FOR SCREENING FOR COMPOUNDS CAPABLE OF MODULATING VEGF EXPRESSION | PTC THERAPEUTICS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005049868-A9 | METHODS AND AGENTS FOR SCREENING FOR COMPOUNDS CAPABLE OF MODULATING HER2 EXPRESSION | PCT THERAPEUTICS INC (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005049868-A1 | METHODS AND AGENTS FOR SCREENING FOR COMPOUNDS CAPABLE OF MODULATING HER2 EXPRESSION | PCT THERAPEUTICS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050048549-A1 | Expression vector comprising regulatory nucleotide sequences for use in identifying modulator of gene expression; identifying modulators which control gene expression via acting untranslated regions of messe ger RNA | PTC THERAPEUTICS, INC. | 2005-03-03 | — | — | US | disclosed |
| US-20040214223-A1 | Methods and agents for screening for compounds capable of modulating VEGF expression | PTC THERAPEUTICS, INC. | 2004-10-28 | — | — | US | disclosed |